Skip to main content

Latest SEC Filings — Page 177

Page 177 · 30 filings scored 7+ · newest 4:14 PM ET · How scores work

Thu, Aug 1330 filings
7UYSCUY Scuti Acquisition Corp.UY Scuti 10-Q: Going Concern Deepens as Cash Dwindles to $8,807Form 10-Q · Periodic report▼ Negative9IVVDInvivyd, Inc.Invivyd Q2 Loss Widens; Going Concern Doubt and Nasdaq Delisting Notice DisclosedForm 10-Q · Periodic report▼ NegativePro9XOSXos, Inc.Xos Q2 Revenue Collapses 74%, Going Concern Warning ReiteratedForm 10-Q · Periodic report▼ NegativePro8CVSICV Sciences, Inc.CV Sciences Q2 Revenue Drops 17.5%, Going Concern Warning ReiteratedForm 10-Q · Periodic report▼ NegativePro8SRTSSensus Healthcare, Inc.Sensus Healthcare Q2 Revenue Misses by 50%, Net Loss Widens to $8.7MForm 8-K · Current report▼ NegativePro8SSTISoundThinking, Inc.SoundThinking Cuts FY2026 Guidance: Revenue Down 9%, EBITDA Margin HalvedForm 8-K · Current report▼ NegativePro8PEWGrabAGun Digital Holdings Inc.GrabAGun Q2 Loss Widens; Material Weaknesses PersistForm 10-Q · Periodic report▼ NegativePro9RKDAArcadia Biosciences, Inc.Arcadia Biosciences Q2 Loss Widens to $6.27M; Going Concern and Nasdaq Delisting Risks MountForm 10-Q · Periodic report▼ NegativePro8FSTJFirst America Resources CorpFirst America Resources Q2 2026: Revenue Up 20%, Going Concern Doubt AlleviatedForm 10-Q · Periodic report▲ PositivePro7ECTMECA Marcellus Trust IECA Marcellus Trust I Q2 Distributable Income Plunges to $0.02MForm 10-Q · Periodic report▼ Negative7BLSMBlossomHill Therapeutics, Inc.Cormorant Discloses 11.79% Stake in BlossomHill After IPO, Including Preferred ConversionsSchedule 13D · Ownership stake● Neutral7DDSDillard's, Inc.Dillard's Q2 EPS Beats on Tariff Refund; Core Retail Margin ExpandsForm 8-K · Current report● Neutral7CRBUCaribou Biosciences, Inc.Caribou's Q2 Loss Narrows to $24.3M; ATM Sales Add $18.3M While Cash Runway Holds at 12 MonthsForm 10-Q · Periodic report● Neutral7AITApplied Industrial Technologies, Inc.Applied Industrial Technologies Files 10-K: Record FY2026 Sales of $5.0B, EPS $10.95, and $317M in BuybacksForm 10-K · Periodic report▲ Positive8QSIQuantum-Si IncQuantum-Si Pushes Proteus Launch to Q2 2027, Reduces Workforce by 20%, and Extends Cash Runway to Q4 2028Form 8-K · Current report▼ NegativePro7MRMDMariMed Inc.MariMed Q2 10-Q: Record Revenue, Wider Loss, and $7M in Disputed IRS LiensForm 10-Q · Periodic report▼ Negative7IDAIT Stamp IncTrust Stamp Reports 22% Revenue Growth, EU IPCEI Selection, and Sovereign AI PushForm 8-K · Current report● Neutral7ASMBAssembly Biosciences, Inc.Assembly Bio Q2 Loss Narrows to $3.9M; Cash Runway Extended into 2029Form 8-K · Current report▲ Positive7RANIRani Therapeutics Holdings, Inc.Rani Therapeutics Q2 2026: RT-114 Expansion Cohort Dosed, Cash Runway Through 2027Form 8-K · Current report● Neutral7HTFLHeartflow, Inc.Heartflow Q2 10-Q: 48% Revenue Growth, $7.5M Impairment, and New Insider Trading PlansForm 10-Q · Periodic report● Neutral7RNXTRenovoRx, Inc.RenovoRx Q2 2026: Record Revenue, Full Enrollment, and Cash Runway Through 2027Form 10-Q · Periodic report▲ Positive7GLASGlass House Brands Inc.Glass House Brands Q2 2026: Record Biomass Production, Positive Adjusted EBITDA, Reaffirms 1M Pound ForecastForm 6-K · Current report▲ Positive8EIKNEikon Therapeutics, Inc.Eikon Therapeutics Q2 2026: Losses Continue, Material Weakness UnresolvedForm 10-Q · Periodic report▼ NegativePro8AVXAVAX One Technology Ltd.AVAX One Posts $35.1M Q2 Loss on Digital Asset Decline; Restructures DebtForm 10-Q · Periodic report▼ NegativePro8ETONEton Pharmaceuticals, Inc.Eton Lifts 2026 Revenue Outlook to $145M+ on 99% Q2 SurgeForm 8-K · Current report▲ PositivePro8KYNBKyntra Bio, Inc.Kyntra Bio Q2: $30.9M Bankruptcy Gain, Nasdaq Delisting Risk, and $7M Indemnification AccrualForm 10-Q · Periodic report▼ NegativePro9CODXCo-Diagnostics, Inc.Co-Diagnostics Flags Going Concern as Cash Drops to $3.6MForm 10-Q · Periodic report▼ NegativePro8IDAIT Stamp IncT Stamp Q2 10-Q: Going Concern Warning, $5.5M Debt, and Massive Warrant OverhangForm 10-Q · Periodic report▼ NegativePro8APURAperture ACAperture AC Q2 2026: Net Income $56K, Trust Account $102.6M, Material Weakness PersistsForm 10-Q · Periodic report▼ NegativePro7GLOBGlobant S.A.Globant Q2 EPS Misses, Guides FY26 Revenue Down ~1%, Names New Glob.AI CEOForm 6-K · Current report▼ Negative
How Wiseek picks and scores these

How Wiseek curates this list

Every filing on this page is sourced directly from SEC EDGAR, the U.S. Securities and Exchange Commission's public filings system. Wiseek processes 8-K, 10-K, 10-Q, Form 4, Form 144, DEF 14A, Schedule 13D/A and related disclosures filed by U.S.-listed companies. The original filing is always linked from each article so readers can verify the source document directly.

How filings get scored

Each filing runs through Wiseek's importance scorer, which weights filing type, deal magnitude, insider participation, material-event flags (going-concern, restatements, executive transitions, M&A) and historical market-reaction patterns. Filings scoring below 7 on the 1–10 scale are filtered out at the database query so this list stays focused on market-moving disclosures. See our methodology for the full rubric.

Editorial standards

Wiseek does not edit the underlying SEC filing. Plain-English summaries and key-event extractions are generated from the verified source text and clearly attributed as AI-generated. Wiseek does not provide investment advice — see our editorial policy for full standards on accuracy, source disclosure, and corrections.

Track by company

Follow all SEC filings for a specific company by visiting its ticker page: AAPL, MSFT, NVDA, TSLA, AMZN, GOOGL, META, JPM, V, UNH, XOM, AVGO, LLY, MA, COST, JNJ, PG, HD, ABBV, MRK, KO, NFLX, AMD, WMT, CVX, BAC — or browse all covered tickers.